Fostamatinib for treating persistent or chronic immune thrombocytopenia – Appraisal Consultation Document

In DRAFT guidance, fostamatinib is not recommended for refractory chronic immune thrombocytopenia because although it was superior to placebo, no direct or indirect data vs rituximab (an appropriate comparator) were provided and thus cost-effectiveness estimates were uncertain.

Source:

National Institute for Health and Care Excellence